Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells $256,075.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $102.43, for a total value of $256,075.00. Following the completion of the transaction, the chief executive officer owned 2,240,000 shares in the company, valued at $229,443,200. This represents a 0.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

iRadimed Stock Performance

Shares of iRadimed stock opened at $99.50 on Friday. The stock has a 50 day moving average of $100.47 and a 200 day moving average of $89.49. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 56.86 and a beta of 1.12. iRadimed Corporation has a fifty-two week low of $47.48 and a fifty-two week high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Analysts forecast that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were issued a $0.20 dividend. This is an increase from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date was Monday, February 23rd. This represents a $0.80 annualized dividend and a yield of 0.8%. iRadimed’s payout ratio is presently 45.71%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IRMD. Lake Street Capital reaffirmed a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Finally, Roth Mkm restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Tuesday, February 10th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, iRadimed has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

Institutional Trading of iRadimed

Large investors have recently modified their holdings of the stock. Hsbc Holdings PLC raised its stake in shares of iRadimed by 19.2% in the fourth quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock valued at $2,103,000 after acquiring an additional 3,468 shares in the last quarter. Aristides Capital LLC increased its holdings in iRadimed by 5.0% during the 4th quarter. Aristides Capital LLC now owns 27,734 shares of the medical equipment provider’s stock worth $2,698,000 after purchasing an additional 1,309 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after purchasing an additional 205,783 shares during the period. Invesco Ltd. raised its position in iRadimed by 473.9% in the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after purchasing an additional 29,010 shares in the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in iRadimed in the 4th quarter valued at about $1,679,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.